Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 1,500 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 1,500 shares of the stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $12.00, for a total value of $18,000.00. Following the sale, the general counsel directly owned 469,301 shares in the company, valued at $5,631,612. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alphatec Price Performance

Shares of ATEC stock traded up $0.06 during trading on Thursday, hitting $10.69. 339,698 shares of the stock traded hands, compared to its average volume of 2,065,634. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The firm's fifty day moving average price is $11.78 and its 200-day moving average price is $11.05. The firm has a market capitalization of $1.56 billion, a P/E ratio of -9.30 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative net margin of 25.77% and a negative return on equity of 1,657.19%. The company had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. During the same quarter last year, the business posted ($0.34) EPS. The firm's revenue for the quarter was up 22.2% on a year-over-year basis. As a group, equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of Alphatec

Institutional investors have recently added to or reduced their stakes in the stock. Comerica Bank increased its holdings in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Quarry LP increased its position in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after acquiring an additional 2,375 shares during the period. Larson Financial Group LLC purchased a new stake in shares of Alphatec during the first quarter worth $54,000. Lazard Asset Management LLC purchased a new stake in shares of Alphatec during the fourth quarter worth $76,000. Finally, AlphaQuest LLC purchased a new stake in shares of Alphatec during the fourth quarter worth $80,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ATEC shares. Piper Sandler reiterated an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 target price on the stock in a research note on Monday, June 16th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Alphatec currently has a consensus rating of "Moderate Buy" and an average target price of $18.13.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.